NCT00300378View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

January 31, 2007

Conditions

Depressive Disorder, Major

Interventions

DRUG

desvenlafaxine 50 mg

DRUG

desvenlafaxine 100 mg

Trial Locations (43)

157

Pretoria

1005

Riga

3008

Jelgava

3401

Liepāja

4058

Durban

4730

Strenči

9301

Bloemfontein

9646

Cape Town

10090

Zagreb

10204

Vilnius

14000

Caen

21000

Split

24100

Salo

26100

Rauma

35000

Rennes

37300

Tours

39100

Dole

41914

Bucharest

44700

Orvault

50185

Kaunas

50407

Tartu

50417

Tartu

51000

Rijeka

59500

Douai

60011

Bucharest

68100

Mulhouse

70110

Kuopio

80100

Joensuu

82606

Bratislava

91251

Klaipėda

97201

Bojnice

97901

Rimavská Sobota

200738

Craiova

126 18

Tallinn

FIN-02650

Espoo

FIN-00100

Helsinki

FIN-00260

Helsinki

FIN-00530

Helsinki

90 100

Oulu

SF-20100

Turku

56-100

Lubiąż

95 080

Tuszyn

09-300

Żuromin

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00300378 - Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter